



Pedal wound and diabetes management is an ever-growing aspect of podiatric practice, and is of particular importance in helping to confirm and maintain the idea of DPMs as integral members of the typical multidisciplinary “wound care team.” Here we present a sampling of both new and established wound care-related products and services available to the podiatric community.

AMERX Announces New LTA Resources, a New Collagen Gel, and Expanded OTC Wound Care Options

One of the biggest Medicare changes in over a decade, the introduction of the Lymphedema Treatment Act (LTA), has a direct effect on both Amerx’s physician partners and their patients. The LTA, which became effective January 1, 2024, brought about significant changes in Medicare’s policy regarding coverage of devices necessary for patients

Continued on page 90



AMERX
HEALTH CARE X
Leader in Wound Care Products

AOTI’s TWO2 Therapy Delivers Oxygen to the Wound Bed for Effective and Durable Healing

AOITI’s mission is to help all people with chronic conditions get back to living life to the fullest. They are committed to enhancing access to care, improving quality of life, and advancing health equity.

Unlike other topical oxygen therapies, only AOTI’s multi-modality Topical Wound Oxygen (TWO2) therapy uses a combination of noncontact cyclical compression, humidification, and higher-pressure delivery of oxygen to the wound bed, resulting in more effective and durable healing.

Several high-quality randomized controlled trials and 5+ systematic reviews and meta-analyses all support the efficacy of topical oxygen in healing chronic wounds. The American Diabetes Association (ADA) awarded topical oxygen therapy an “A” grade treatment recommendation two years in a row in their Standards of Care. Additionally, the International Working Group on the Diabetic Foot (IWGDF) and Wound Healing Society (WHS) also recommend topical oxygen use in their recent clinical practice guidelines.

AOTI’s patented non-invasive Topical Wound Oxygen (TWO2) therapy is the only device that has demonstrated in Randomized Controlled Trial (RCT) and Real-World Evidence (RWE) studies to more durably heal Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88% reduction in hospitalizations and 71% reduction in amputations over 12 months. The therapy can be utilized in any clinical setting and is com-



monly administered by patients at home. This helps to improve therapy compliance and improves access to care, while enhancing health equity, clinical outcomes and reducing costs.



AOTI’s NEXA NWPT System

For patients requiring negative pressure wound therapy, AOTI’s NEXA™ NPWT System provides uncompromising treatment for patients with chronic and acute wounds. This multi-week, multi-patient, disposable system is simple, portable and affordable. It is lightweight, compact, with a handy carrying case and 10-hour battery life. The NEXA System is designed to operate for 8 weeks (56 days). Usable hours are depleted only when the device is providing therapy; remaining hours can be used at your convenience on the next patient.

Visit aotinc.net or click here for more information.



to properly manage their condition. This new prevention policy is long overdue and has wide-reaching impacts on the practice management and reimbursement of these devices for participating DME providers.

Following the announcement of the LTA, AMERX partnered with experts in practice management, coding, documentation, and with physicians who have built successful multi-location practices. Their goal was to gather all the information necessary for their AMERX partners to provide LTA benefits to their patients. AMERX is now providing these resources to their partners, in addition to sponsoring continuing education events to help get the word out about LTA and its benefits.

AMERX is also now offering three kinds of collagen, expanding the HELIX3[®] brand with the additions of a NEW 7g. Collagen Gel, Wound Care Kits, and an OTC Wound Recovery Kit. This NEW collagen gel contains over 92% of collagen solids. AmerX has also created OTC Wound Care options for patients with poor coverage or high out-of-pocket expenses.

Visit AMERXHC.com or click here.

Vaporox Improves Health of Wounded Tissue by Alternating Hydrating Vapor and Concentrated Oxygen

Vaporox is a unique patented FDA-cleared technology for the treatment of nine types of chronic skin wounds. Used as an adjunct to standard wound care, it uses a proprietary combination of hydrating vapor and concentrated oxygen, and has been shown in studies to significantly improve the healing results of standard wound care.

“The effectiveness of Vaporox in my clinic has dramatically improved my patient outcomes.,” says Dr. Dustin Kruse, DPM.

Vaporox technology consistently granulates wound beds 50-70% by volume in just 4-6 weeks, resolving chronic wounds in an average of 9.4-weeks.

For providers who use cellular tissue products, Vaporox is an excellent choice to prepare wound



beds and accelerate time to closure.

Vaporox requires no up-front capital investment. With an approved category 1 CPT code and pay-per-use model, providers can quickly integrate this technology into their practice.

Podiatrists nationwide report improved patient outcomes while developing a solid private practice wound care business model.

Visit www.vaporox.com or click here for more information, or contact them at info@vaporox.com.



Jumpstart Your Hard-to-Heal Wounds

Jumpstart your hard-to-heal wounds with Hartmann’s ColActive[®] Plus collagen sheets. Made from a patented blend of Collagen, EDTA, Alginate and CMC, this unique formulation significantly lowers select excess MMP activity and maintains wound pH levels that do not harm growth factors, plasma proteins and other cell types that are required for wound healing.

ColActive[®] Plus has multiple modes of action: The fish-derived collagen attracts harmful excess MMPs from the wound, and EDTA deactivates these MMPs by binding with zinc ions. The alginate and CMC transform into a soft gel to absorb excess MMPs and maintain an optimal moisture balance.

Dr. Windy Cole discusses the importance of this in her article, “Antimicrobial Resistance and Stewardship in Wound Management” in this issue. According to the article, “Ethylene-

diaminetetraacetic acid (EDTA) has shown antimicrobial/antibiofilm activity through chelation of calcium, magnesium, iron and zinc to destabilize bacteria cell walls leading to cell destruction. Advanced wound dressings containing EDTA, like ColActive[®] Plus, remove zinc to inhibit the activity of bacteria and matrix metalloproteinases (MMPs), thus creating a suitable environment for wound healing.”

ColActive[®] Plus is available in multiple sizes in non-silver and silver versions. For more information, call 1-800-243-2294, visit www.hartmannusa.com, or click here.

StimLabs Receives FDA 510(k) Clearance for Corplex P

StimLabs[®] has received FDA 510(k) clearance for Corplex P, the pioneering human umbilical cord-derived medical device. This first-of-its-kind clearance highlights StimLabs’ position on the leading edge of the wound care industry.

StimLabs introduced the first-ever full thickness, intact placental membrane allograft in 2016, and now continues its commitment to innovation with this unprecedented 510(k) clearance, “StimLabs was built as a forward-thinking company, focused on pushing boundaries and driving advancements that redefine standards and progress in healthcare,” says Founder and CEO, John Daniel. “Receiving 510(k) clearance for Corplex P is yet another step in our journey.”

Corplex P is a particulate device derived from human umbilical cord extracellular matrix (ECM) indicated for the management of acute and

Continued on page 91



MiMedx Group, Inc. Introduces EPIEFECT™

EPIEFECT expands Mimedx's core AWC offering for clinicians treating acute and chronic, hard-to-heal wounds such as diabetic foot ulcers ("DFUs") and venous leg ulcers ("VLUs"), among other common conditions. EPIEFECT offers a thick, tri-layer configuration that is suitable for securing the graft in place with sutures. In addition, its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds.

"We are delighted to introduce another innovation in the wound & surgical marketplace," said Joseph H. Capper, MIMEDX CEO. "EPIEFECT provides a thick, tri-layer option to our customers, including those in the private physician office setting. Our approach is to provide the most clinically effective and evidence-based products possible in the markets we serve—products designed to meet specific customer demand and use cases. We believe EPIEFECT effectively addresses the need for a robust allograft solution, available in an assortment of sizes, to address complex wounds in-office before hospital-based inter-

vention may be required."

Dr. Christopher Gill, D.P.M., M.S., a podiatrist at the McLaren Bay Region Wound Care Center in Bay City, Michigan added, "I am very excited to incorporate EPIEFECT into my wound care

treatment strategy.

As a longtime advocate of EPIFIX, I have seen firsthand how MIMEDX's product portfolio can be ideally suited for a variety of patients in need of an allograft solution."

Mr. Capper continued, "As we have been preparing for its launch, customer anticipation for EPIEFECT is high and we look forward to seeing how this product can help patients with chronic and hard-to-heal wounds."

To learn more, please visit <https://www.mimedx.com/epieffect/> or click here.



chronic wounds. Its versatile format, conformability, and retention of ECM components such as collagen and glycosaminoglycans, make it a valuable device in the treating physician's armamentarium.

Corplex P will be available soon for use in medical settings. For further information, visit <https://bit.ly/3VX5wGR> or click here.

About StimLabs

Stimlabs LLC was founded in 2015 with the mission to advance the state of regenerative medicine with a current focus in wound care

and surgical applications. <https://bit.ly/3VZ8jPW>.

Data on file. Patents: <http://www.stimlabs.com/patents> © Stimlabs® LLC; STIMLABS and CORPLEX P are trademarks of Stimlabs LLC. 1225 Northmeadow Parkway, Suite 104, Roswell, GA 30076

APWH Launches Innovative Wound Management Certification Course Amid Growing Demand

The Academy of Physicians in Wound Healing (APWH), the leading global professional association dedicated to enhancing patient outcomes in complex chronic wound care, proudly announces the launch of its new Prescribers Advanced Wound Management Certification Course.

As wound care continues to evolve without formal specialty recognition by the American Board of Medical Specialties (ABMS), the Academy remains committed to pioneering advancements in medical training. "Our mission is to elevate

our educational offerings to the stature of a recognized medical specialty, ensuring our members deliver the highest standard of patient care," remarked Steven Kravitz, DPM, President of APWH. "This new course is meticulously designed with up-to-date content, incorporating research



and practices from the past five years to keep pace with current medical standards," he added.

The course covers essential topics such as maintaining skin integrity, managing chronic, arterial, and venous ulcers, diabetic foot wounds, atypical wounds, skin substitutes, CTPs/CAMPS, and much more. Upon completing the course, eligible candidates may take the appropriate certification exam through the Council of Medical Education and Testing



(CMET), which provides credentials to a broad spectrum of healthcare professionals, including physicians, nurse practitioners, physician assistants, nurses, and physical therapists.

“The demand for this innovative course has exceeded our expectations, with both members and non-members enrolling,” said Fredrick Berg, CEO of APWH.

For more information, please visit apwh.org or [click here](#).

About APWH:

The Academy of Physicians in Wound Healing (APWH) is a premier global professional association dedicated to enhancing the lives of patients grappling with complex chronic wounds. With an unwavering commitment to excellence, APWH endeavors to redefine the standards of wound care through groundbreaking education, advocacy, and research initiatives.

Physician’s Own Introduces NanoGEL Plus

Physician’s Own proudly introduces NanoGEL Plus, an innovative gel that combines an all-natural proprietary blend with the potent antimicrobial properties of Nano Silver, synergistically enhanced by Nano CBD THC-free isolate. Together, they form a dual-action formula that effectively targets infections while promoting natural anti-inflammatory processes.

NanoGEL Plus is designed to arrest biofilm formation and disrupt pathogen replication while providing anti-inflamma-



tory benefits to various wound types, including post-op incisions, diabetic ulcers, venous ulcerations, abrasions, and minor burns.

David Corcoran, DPM, Chief Medical Advisor at Physician’s Own, expressed his enthusiasm, saying: “My use of NanoGEL Plus has yielded extremely positive and gratifying results. I’m confident that providers who use it in their practice will achieve the same.”

For ordering and more information about NanoGEL Plus and the full line of Physician’s

Own products, please visit NANO-GELPLUS.COM, [click here](#), or contact INFO@NANO-GELPLUS.COM.